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OBJECTIVE: To estimate C/E and C/U of INFbeta-1b 8
MIU every second day in RRMS in comparison to pla-
cebo. METHODS: The model for the Polish health care
context was developed, based on the use of clinical data
from literature and local data on health care resource uti-
lization and unit cost. The current trial evidence suggests
a significant effect only on the number of relapses, there-
fore a very simple model was constructed, which calcu-
lated cost savings and QALY gains from reductions in
the number of relapses. Only direct medical costs were
analyzed. The perspective of health care payers, time ho-
rizon of two years and discount rate 5% were used. The
primary clinical outcomes were: for CEA, the avoided re-
lapses, and for CUA, QALY. Utility values were obtained
from EQ-5D survey, reported in the randomized trial, or
calculated, making many assumptions based on clinical
opinion, using the Index of Health-Related Quality of
Life. RESULTS: INFbeta-1b decreased the number of re-
lapses by 86/100 patients/2 years. The estimated increase
in QALY per relapse avoided was 0.072 (EQ-5D) or 0.073–
0.082, depending on the severity of relapses (IHRQL). The
QALYs gained by INFbeta-1b over 2 years were estimated
at 6.2 (EQ-5D) or 0.95-7 (IHRQL) for 100 patients. Over
2 years the costs for 100 patients in INFbeta-1b group
were by 14 548 277 PLN higher than in placebo (1 USD 
4.5 PLN). Cost per relapse avoided was 173504 PLN.
Cost per QALYs gained was 2 406 663 PLN or 2 131
616-15 706 642 PLN respectively for EQ-5D and IHRQL
estimation of utility. Sensitivity analysis showed, that C/
U ratio might have an acceptable value (60 000 PLN/
QALY), if the cost of INFbeta-1b decreased by 95% or
the number of QALYs gained increased 40-fold. CON-
CLUSIONS: The high C/U ratio was driven by the cost of
INFbeta-1b and the modest clinical effect.
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OBJECTIVE: Develop a conjoint questionnaire to evalu-
ate patient preferences regarding side effects from anti-
epileptic medications. METHODS: We performed an ex-
tensive literature review and consulted with experts to
identify the constructs of interest. We conducted two
rounds of cognitive interviews with epilepsy patients to
pretest the questionnaire. Between the two sets of inter-
views, the questionnaire was revised to address issues
identified during the first interviews and to incorporate
further advice from a physician specializing in epilepsy.
The second set of interviews was undertaken to assess the
efficacy of the questionnaire modifications. RESULTS:
The combination of these survey design methods greatly
facilitated the development of the conjoint questionnaire
(now ready for use in a full-scale field test). The involve-
ment of patients with epilepsy in the cognitive pretest
provided valuable insights that the literature review and
physician consultations failed to identify. Potential prob-
lems identified and addressed related to the background
questions, the choice of side effects and the descriptions
of the side effects. For example, some of the original side
effects were not particularly familiar or salient to pa-
tients, and were subsequently replaced by alternatives
identified by epilepsy patients interviews and the physi-
cian in his experience with epilepsy patients as more im-
portant. Unexpectedly, we found that respondents fo-
cused first on the potential for driving restrictions when
ranking potential medications. The other side effects were
used only to distinguish between alternatives that did not
differ in their potential for driving restrictions. CON-
CLUSIONS: Although they tend to be under-utilized
within the pharmaceutical industry, cognitive methods
are extremely important tools for examining the thought
processes that affect the quality of answers provided to
questionnaire items. The qualitative information gath-
ered in the patient pretests was a necessary element of the
conjoint instrument design, and helped us to maximize
the comprehensibility and psychometric soundness of the
final questionnaire.
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OBJECTIVE: To determine the utility of a model using
prescription directions versus administrative data to esti-
mate cost savings of a 2:1 gabapentin capsule-to-tablet
interchange protocol from the perspective of an outpa-
tient prescription formulary decision-maker. METHODS:
Database analyses were based on 1852 outpatient pre-
scriptions (712 new, 1140 refills) for gabapentin 300 and
400 mg capsules dispensed at the McGuire Veterans Af-
fairs Medical Center between 5/1/99–4/30/00. A model
was constructed to identify all clinically appropriate con-
vertible prescriptions to yield annual convertible doses.
Over 256 unique prescription directions were analyzed
and assigned to one of 26 prescribing groups. All 1853
prescriptions were then assigned to one of 5 categories (4
non-convertible and 1 convertible category) based on
these groups. Analysis of administrative data identified
2:1 convertible prescriptions if division of quantity dis-
pensed by days supply fields yielded even whole numbers.
A second, conservative approach assumed three times
daily dosing regimens (manufacturer’s recommended guide-
lines) to identify 2:1 conversions. Cost savings were cal-
culated using $0.11 and $0.14 (U.S.) saved per each in-
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terchangeable 300 and 400 mg dose. RESULTS: Model
data captured 99% of all feasible 2:1 interchanges. Cost
savings predicted form administrative data varied be-
tween 82 and 150 percent of actual savings using the pre-
scription direction model. CONCLUSIONS: Administra-
tive pharmacy data is a poor predictor of cost savings for
2:1 interchange protocols for medications with highly
variable dosing regimens such as gabapentin. A model
utilizing prescription directions may be beneficial in for-
mulary decision-making where highly accurate estimates
are necessary.
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OBJECTIVE: The Disability in Strategies for Care (DISC)
study compared, in 835 patients, a stratified care strat-
egy, where initial therapy for migraine is based on clini-
cal need, and two stepped care strategies (across attacks
and within attacks), where first-line therapy with simple
analgesic is escalated, if response has been inadequate, to
zolmitriptan—a migraine-specific therapy. We report on
a stochastic cost-effectiveness analysis (CEA) of these
three strategies. METHODS: The analysis adopted a so-
cietal perspective, including health service and productiv-
ity costs (1998–1999 prices). Data were collected on drug
usage (main therapy, rescue and adverse event manage-
ment); other resource use associated with adverse events
was estimated by a clinician blinded to treatment strat-
egy. Productivity costs were based on diary card data for
time patients lost from work, and on reduced effective-
ness at work. CEA related differential cost to the trial’s
two primary outcome measures: headache response at
two hours and disability-adjusted time over 4 hours. RE-
SULTS: Total mean cost over six attacks was lowest in
the stratified group (£138.95; 95% CI 122.38, 158.93)
compared to £157.19 (95% CI 134.50, 184.93) in the
stepped across attacks group and £148.53 (95% CI
123.04, 179.41) in the stepped care within attacks group.
Both measures of effectiveness showed an improvement
in the stratified arm. In terms of mean costs and effects,
stratified care represents a dominant strategy. Cost-effec-
tiveness acceptability curves indicate that, depending on
the value that decision-makers place on a unit of out-
come, the probability that stratified care is the most cost-
effective strategy ranges from 58% to 100% for the 2-
hour response rate and from 62% to 98% for disability-
adjusted time. CONCLUSION: Given its lower mean
costs and higher mean effectiveness, stratified care, which
included zolmitriptan, is the dominant strategy. When
uncertainty is considered, stratified care has the highest
probability of being cost-effective.
PNR5
THE LONG-TERM ECONOMIC IMPACT OF 
TREATING ALZHEIMER’S PATIENTS IN SWEDEN 
WITH GALANTAMINE
Garfield FB1, Getsios D2, Mehnert A3, Wallin A4 for the 
AHEAD Study Group
1Caro Research, Concord, MA, USA; 2Caro Research, 
Montreal, QC, Canada; 3Janssen Research Foundation, Beerse, 
Belgium; 4Institute of Clinical Neuroscience, Sahlgrenska 
University Hospital, Göteborg University, Mölndal, Sweden
OBJECTIVE: Estimate the long–term health and economic
impact in Sweden of treating patients with mild to moderate
Alzheimer’s disease (AD) with galantamine. METHODS:
The estimates are derived from an economic model con-
sisting of two parts. The short–term component was based
on the galantamine clinical trials. The long-term compo-
nent predicted, on the basis of trial results and equations
derived from recently published data, when patients
would require full time care (FTC) or die. Resources used
before FTC and for FTC were estimated from the litera-
ture, using an overall health care payer perspective. RE-
SULTS: Approximately 5.6 patients must start treatment
to avoid one year of FTC. Overall net savings of galan-
tamine compared to no treatment ranged from SEK
27,500 (all subjects) to SEK 59,000 (moderate patients
only). Univariate and multivariate sensitivity analyses of
key parameters, such as the cost of galantamine, cost of
FTC not in a nursing home (NH), cost of FTC in NH and
proportion of FTC patients in NH, supported the robust-
ness of these findings. For instance, a multivariate sensi-
tivity analysis found that if the cost of FTC outside a NH
is 50% of NH costs, instead of the 71% reported in the
literature, and only 50% of patients requiring FTC reside
in NH instead of the reported 85%, the net savings are
SEK 10,400. CONCLUSION: Galantamine therapy de-
lays the need for FTC without leading to additional cost
in the treatment of mild to moderate AD in Sweden.
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OBJECTIVES: Epilepsy and its treatment can have pro-
found effects on the quality of life (QOL) of many pa-
tients, particularly those with seizures refractory to treat-
ment. Detecting changes in QOL in trials of anti-epileptic
drugs as add-on therapy over a short period is, however,
known to be difficult. METHODS: In this study, we ex-
amined the relationship between patients’ perception of
quality of life change, using QOL transition scales, and
